Clinical Trial Update: BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluates BMS-275291 for HIV-related Kaposi's sarcoma. The study is sponsored by the National Cancer Institute.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kaposi Sarcoma

Drugs mentioned

• BMS-275291

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Sarcoma | Phase 1, Phase 2 | Status: COMPLETED